Pelthos Therapeutics Reports 114% Surge in Third-Quarter Revenue

Pelthos Therapeutics Inc. posted a 114% year-over-year increase in net product revenue for its flagship product, Zelsuvmi, during the third quarter of 2026. Chief Executive Officer Scott Plesha reported that the product generated $15.2 million in net revenue for the quarter. Across five quarters since its commercial rollout, the company has dispensed over 40,000 units and treated more than 31,000 patients.

Alongside the revenue growth, leadership outlined strategies to broaden the company's dermatology portfolio through upcoming commercial launches for Xepi and Xeglyze. Pelthos also intends to branch out into the rare disease gene therapy space by acquiring Castle Creek Biosciences. This planned merger, slated to close in the first quarter of 2027, is set to introduce a Phase III cell therapy candidate to the firm's existing lineup of FDA-approved products.

Management noted that Zelsuvmi achieved higher prescriber adoption and improved formulary coverage despite facing seasonal headwinds affecting molluscum contagiosum claims. In early October, the company secured a major pharmacy benefit manager agreement providing commercial coverage for 24 million lives, complemented by a regional health plan update adding approximately 3 million covered lives.

What to watch next: Monitor the completion of the Castle Creek Biosciences acquisition and the upcoming product rollouts for Xepi and Xeglyze.